Article Versions Notes

Mesquita FP, Souza PFN, da Silva EL, Lima LB, de Oliveira LLB, Moreira-Nunes CA, Zuercher WJ, Burbano RMR, de Moraes MEA, Montenegro RC. Kinase Inhibitor Screening Displayed ALK as a Possible Therapeutic Biomarker for Gastric Cancer. Pharmaceutics. 2022; 14(9):1841. https://doi.org/10.3390/pharmaceutics14091841

Mesquita, Felipe Pantoja, Pedro Filho Noronha Souza, Emerson Lucena da Silva, Luina Benevides Lima, Lais Lacerda Brasil de Oliveira, Caroline Aquino Moreira-Nunes, William J. Zuercher, Rommel Mario Rodríguez Burbano, Maria Elisabete Amaral de Moraes, and Raquel Carvalho Montenegro. 2022. "Kinase Inhibitor Screening Displayed ALK as a Possible Therapeutic Biomarker for Gastric Cancer" Pharmaceutics 14, no. 9: 1841. https://doi.org/10.3390/pharmaceutics14091841

Mesquita, F. P., Souza, P. F. N., da Silva, E. L., Lima, L. B., de Oliveira, L. L. B., Moreira-Nunes, C. A., Zuercher, W. J., Burbano, R. M. R., de Moraes, M. E. A., & Montenegro, R. C. (2022). Kinase Inhibitor Screening Displayed ALK as a Possible Therapeutic Biomarker for Gastric Cancer. Pharmaceutics, 14(9), 1841. https://doi.org/10.3390/pharmaceutics14091841